首页> 外文期刊>Expert opinion on investigational drugs >New therapeutic approaches to subarachnoid hemorrhage
【24h】

New therapeutic approaches to subarachnoid hemorrhage

机译:蛛网膜下腔出血的新治疗方法

获取原文
获取原文并翻译 | 示例
       

摘要

Introduction: Subarachnoid hemorrhage (SAH) is associated with significant morbidity and mortality, even for patients who receive early neurointerventionist management. Areas covered: Early mechanisms of secondary brain injury precede the delayed vasospasm phase and contribute to the poor outcome. These mechanisms and their intervention are discussed, including high intracranial pressure (ICP), low cerebral perfusion pressure (CPP), acute vasospasm, disturbed cerebral autoregulation, cerebral edema, oxidative stress, seizures, microvascular damage and hyperglycemia. Erythropoietin, statins and magnesium have been particularly promising in experimental studies. Expert opinion: Multiple mechanisms, including delayed vasospasm, may contribute to cerebral ischemia and poor outcome following SAH. Treatments that simultaneously target multiple secondary injury pathways show significant potential as therapeutic agents, particularly those that attenuate vasospasm in addition to having other neuroprotective properties.
机译:简介:蛛网膜下腔出血(SAH)与明显的发病率和死亡率相关,甚至对于接受早期神经干预治疗的患者也是如此。涵盖的领域:继发性脑损伤的早期机制在延迟的血管痉挛阶段之前,并导致不良的预后。讨论了这些机制及其干预措施,包括高颅内压(ICP),低脑灌注压(CPP),急性血管痉挛,脑自动调节障碍,脑水肿,氧化应激,癫痫发作,微血管损伤和高血糖症。促红细胞生成素,他汀类药物和镁在实验研究中特别有希望。专家意见:SAH术后多种机制,包括延迟的血管痉挛,可能导致脑缺血和不良预后。同时靶向多种继发性损伤途径的治疗方法显示出作为治疗剂的巨大潜力,特别是除了具有其他神经保护特性之外,还可以减轻血管痉挛的治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号